Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the proposed new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; and (vi) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in conne
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   ICD-10 Charts ... months of development, it has officially launched its ... Charts Training Academy and the new 4 Step ... well as all other ICD-10 Charts resources and ... in America, completely free-of-charge.  With the release of ...
(Date:7/7/2015)... Berger & Montague, P.C., a full-spectrum ... with one of the largest and most successful ... and Faruqi, LLP in settling three separate but ... LP, Cephalon, Inc., and Biogen, Inc., for a ... the agreements, AstraZeneca will pay the largest sum, ...
(Date:7/7/2015)... , July 7, 2015 Sequent ... on developing innovative devices for the treatment of ... Kleine has joined its Board of Directors. ... years of medical device and healthcare industries experience. ... where he has commercialized numerous leading-edge products.  His ...
Breaking Medicine Technology:ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 2AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 3Sequent Medical Appoints Mike Kleine to its Board of Directors 2Sequent Medical Appoints Mike Kleine to its Board of Directors 3
... Bioness Inc. today announced that the company has ... further examine the impact of its NESS L300 wireless neurostimulation ... stroke. The FASTEST study aims to demonstrate the superiority of ... an ankle-foot orthosis (AFO), and has enrolled 176 patients at ...
... move that seeks to cut health care costs, create jobs, and ... awarded a grant worth up to $35 million over the next ... (NIPTE) to improve drug manufacturing standards. The grant comes ... to market in the U.S. exceeds $1 billion and an increasing ...
Cached Medicine Technology:Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study 2FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process 2
(Date:7/7/2015)... ... 2015 , ... Today, the physicians at Allied Anesthesia, who provide services to ... Bernardino counties, released a series of tips to help children stay safe over the ... who spend more unsupervised time outdoors. , The most common causes of injuries ...
(Date:7/7/2015)... ... July 07, 2015 , ... WiseWear®, a wearable startup ... first line of luxury smart jewelry called the Socialite™ collection. The product line ... fall. , “The Socialite collection was crafted to inspire women to be ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... growth strategy expert Jay Warden as Senior Vice President, heading the firm’s Healthcare ... to provide the best solutions to healthcare providers’ needs in ways that strengthen ...
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... Refining convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and ... mobile program, surpassing their original 2015 fundraising goal by nearly $100,000, to ...
(Date:7/7/2015)... ... July 07, 2015 , ... Difass USA, a modern supplement brand committed ... stressful days at work is knowing that there is hopefully a vacation to look ... free as imagined. Planning for a vacation can be quite stressful, and it’s difficult ...
Breaking Medicine News(10 mins):Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 2Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 3Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3
... Ormond Street Hospital have developed a way of testing the ... known that very young children have a problem in breathing ... function tests. ,The researchers have devised a method ... of five years. The test was presented at the launch ...
... Seven women doctors have been suspended for their alleged ... sting operation beamed yesterday. // ,The doctors ... (Kota), Priyanaka Saxena (Sawaimadhopur), Madhu Mathur (Jhalawar), Rajkumar Choudhary ... on "awaiting posting order" and asked to report to ...
... Sun Pharmaceutical Industries Ltd today said it has allotted 61,716 ... into equity shares by FCCB holders. // ,The ... equity shares of Rs five each of the company at ... FCCBs of 1000 dollar each, the company informed the Bombay ...
... has revealed that only about 50% of the people are ... Mater Hospital in North Dublin. ,Nearly 4 among ... stance that the new hospital comes up at Mater. There ... wrong note, and now the opposition parties have requested the ...
... An analysis of records of pancreatic surgery during the ... by pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel ... Medical College of Thomas Jefferson University and Thomas Jefferson ... and his colleagues have revealed that contrary to what ...
... intestinal surgery, including stomach reduction for obesity, may increase ... of the study have been published in the British ... on three patients with increasingly poor eyesight or night ... space of a year. None of the patients had ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: